V. J.

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival (2005)

  • Alvi,
  • A.J.,
  • Austen,
  • B.,
  • Weston,
  • V.J.,
  • ...

B-cell chronic lymphocytic leukemia (B-CLL) is a clinically variable disease where mutations in DNA damage response genes ATM or TP53 affect the response to standard therapeutic agents. The in vitro...

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity (2004)

  • Hartley,
  • J.A.,
  • Spanswick,
  • V.J.,
  • Brooks,
  • N.,
  • ...

SJG-136 (NSC 694501) is a rationally designed pyrrolobenzodiazepine dimer that binds in the minor groove of DNA. It spans 6 bp with a preference for binding to purine- GATC-pyrimidine sequences. The...

Etanercept-induced systemic lupus erythematosus (2003)

Tumour necrosis factor (TNF) is a pro-inflammatory cytokine with a role in the pathogenesis of a number of conditions including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing...

Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma (2002)

  • Spanswick,
  • V.J.,
  • Craddock,
  • C.,
  • Sekhar,
  • M.,
  • ...

Melphalan is widely used as a preparative agent in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (SCT). Although disease relapse is the major cause of death...

Data Communications (2000)

 
Additional Information

Publishing period:

1997 - 2006 (23)

Co-authors: